FOLD

8.02

2.17% 0.17

Handel nachbörslich: 8.02

Amicus Therapeutics Inc (FOLD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt FOLD? Forum Prognose

Schlusskurs vom Vortag:

$7.85

Offen:

$7.83

24-Stunden-Volumen:

5.53M

Relative Volume:

1.22

Marktkapitalisierung:

$2.47B

Einnahmen:

$493.67M

Nettoeinkommen (Verlust:

$-104.69M

KGV:

-23.59

EPS:

-0.34

Netto-Cashflow:

$-31.51M

1W Leistung:

+4.84%

1M Leistung:

+17.42%

6M Leistung:

-11.96%

1J Leistung:

-30.38%

1-Tages-Spanne:

$7.81

$8.03

1-Wochen-Bereich:

$7.56

$8.03

52-Wochen-Spanne:

$5.51

$12.65

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Firmenname

Amicus Therapeutics Inc

Sektor

Healthcare (1151)

Branche

Biotechnology (650)

Telefon

(609) 662-2000

Adresse

47 HULFISH STREET, PRINCETON, NJ

Mitarbeiter

499

Twitter

@amicusrx1

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

FOLD's Discussions on Twitter

Vergleichen Sie FOLD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FOLD Amicus Therapeutics Inc	8.02	2.43B	493.67M	-104.69M	-31.51M	-0.34
VRTX Vertex Pharmaceuticals Inc	396.93	102.81B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	453.54	58.59B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	567.22	61.25B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	733.66	43.23B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	318.73	36.53B	3.81B	-644.79M	-669.77M	-6.24

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-17	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-12-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-09-06	Eingeleitet	Jefferies	Buy
2024-05-30	Eingeleitet	Wells Fargo	Overweight
2024-05-14	Hochstufung	Guggenheim	Neutral → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-04-13	Fortgesetzt	Goldman	Neutral
2022-01-14	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-15	Hochstufung	Stifel	Hold → Buy
2021-09-30	Hochstufung	JP Morgan	Neutral → Overweight
2021-07-19	Fortgesetzt	BTIG Research	Buy
2021-05-27	Eingeleitet	Needham	Hold
2021-05-21	Eingeleitet	UBS	Buy
2021-04-14	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2021-03-02	Eingeleitet	Stifel	Hold
2021-02-12	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-28	Fortgesetzt	Cantor Fitzgerald	Overweight
2020-12-10	Herabstufung	Citigroup	Buy → Neutral
2020-11-11	Eingeleitet	Berenberg	Hold
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-02-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-11-12	Bestätigt	H.C. Wainwright	Buy
2019-06-17	Eingeleitet	H.C. Wainwright	Buy
2019-06-05	Bestätigt	Cantor Fitzgerald	Overweight
2019-04-05	Eingeleitet	Janney	Buy
2019-01-30	Eingeleitet	Cantor Fitzgerald	Overweight
2018-10-29	Eingeleitet	Citigroup	Neutral
2018-08-17	Herabstufung	Chardan Capital Markets	Buy → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral
2017-09-13	Bestätigt	Chardan Capital Markets	Buy
2017-08-10	Bestätigt	Chardan Capital Markets	Buy
2017-01-24	Hochstufung	Robert W. Baird	Neutral → Outperform
2016-05-18	Eingeleitet	BofA/Merrill	Buy
2016-04-14	Eingeleitet	Robert W. Baird	Neutral
2016-04-12	Bestätigt	Chardan Capital Markets	Buy
2015-09-16	Herabstufung	Chardan Capital Markets	Buy → Neutral
2015-06-16	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten

Sep 03, 2025

Russell Investments Group Ltd. Purchases 89,287 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat

Sep 03, 2025

Wall Street Zen Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold - MarketBeat

Sep 03, 2025

Real time social sentiment graph for Amicus Therapeutics Inc.2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser

Sep 03, 2025

PDT Partners LLC Grows Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat

Sep 03, 2025

Is Amicus Therapeutics Inc. reversing from oversold territory2025 Top Decliners & Weekly Top Gainers Alerts - Newser

Sep 03, 2025

Ranking Amicus Therapeutics Inc. among high performing stocks via toolsCEO Change & Long-Term Capital Growth Strategies - Newser

Sep 03, 2025

Reversal indicators forming on Amicus Therapeutics Inc. stockJuly 2025 Drop Watch & Reliable Price Breakout Alerts - Newser

Sep 03, 2025

Using Python tools to backtest Amicus Therapeutics Inc. strategiesCEO Change & Reliable Price Action Trade Plans - Newser

Sep 03, 2025

Earnings visualization tools for Amicus Therapeutics Inc.2025 AllTime Highs & Verified Short-Term Plans - Newser

Sep 03, 2025

How to build a custom watchlist for Amicus Therapeutics Inc.2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - Newser

Sep 03, 2025

Applying Wyckoff theory to Amicus Therapeutics Inc. stockJuly 2025 Levels & Safe Capital Investment Plans - Newser

Sep 03, 2025

Is Amicus Therapeutics Inc. stock a buy or sell getLinesFromResByArray error: size == 0 - mustnews.co.kr

Sep 03, 2025

Sep 02, 2025

Has Amicus Therapeutics Inc. found a price floorMarket Risk Analysis & Low Risk High Reward Trade Ideas - Newser

Sep 02, 2025

What makes Amicus Therapeutics Inc. stock price move sharplyJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - Newser

Sep 02, 2025

Amicus Therapeutics Inc. stock momentum explainedM&A Rumor & Safe Entry Point Identification - Newser

Sep 02, 2025

Evaluating Amicus Therapeutics Inc. with trendline analysisWeekly Trade Analysis & Fast Gaining Stock Reports - Newser

Sep 02, 2025

Analyzing Amicus Therapeutics Inc. with risk reward ratio chartsWeekly Market Outlook & Target Return Focused Stock Picks - Newser

Sep 02, 2025

Price Channel Expanding on Amicus Therapeutics Inc.’s Chart getLinesFromResByArray error: size == 0 - thegnnews.com

Sep 02, 2025

Exit strategy if you’re trapped in Amicus Therapeutics Inc.July 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser

Sep 02, 2025